Mark J. Gergen
2022 - Poseida Therapeutics
In 2022, Mark J. Gergen earned a total compensation of $4.4M as Chief Executive Officer, President and Chairman at Poseida Therapeutics, a 55% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $342,280 |
|---|---|
| Option Awards | $1,752,012 |
| Salary | $565,750 |
| Stock Awards | $1,696,700 |
| Other | $12,710 |
| Total | $4,369,452 |
Gergen received $1.8M in option awards, accounting for 40% of the total pay in 2022.
Gergen also received $342.3K in non-equity incentive plan, $565.8K in salary, $1.7M in stock awards and $12.7K in other compensation.
Rankings
In 2022, Mark J. Gergen's compensation ranked 756th out of 5,505 executives tracked by ExecPay. In other words, Gergen earned more than 86.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 756 out of 5,505 | 86th |
Division Manufacturing | 339 out of 2,984 | 89th |
Major group Chemicals And Allied Products | 108 out of 1,339 | 92nd |
Industry group Drugs | 95 out of 1,242 | 92nd |
Industry Biological Products, Except Diagnostic Substances | 22 out of 287 | 92nd |
Source: SEC filing on April 26, 2023.
Gergen's colleagues
We found three more compensation records of executives who worked with Mark J. Gergen at Poseida Therapeutics in 2022.